Developer docs
API playgroundTry for free, no card

Search company profiles

Alchemedicine

Full company profile

uuid0003dio

Namestring
Alchemedicine
Legal namestring
株式会社アークメディスン
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Alchemedicine (株式会社アークメディスン) is a privately held Japanese biotechnology company headquartered in Tsukuba, founded in 2019 and operating with 1-10 employees. The company specializes in the research and development of new low-molecular-weight pharmaceuticals, anchored by its proprietary HiSAP® drug discovery synthesis platform. HiSAP® is described as a synthesis technology designed to rapidly address limitations of existing drug candidates, including weak efficacy, strong side effects, and inadequate in vivo pharmacokinetics, and is positioned as applicable across multiple disease areas with high unmet medical need.

Short descriptiontext

Alchemedicine is a Tsukuba, Japan-based biotechnology company that uses its proprietary HiSAP® drug discovery platform to develop improved small-molecule therapeutics, licensing preclinical and clinical-stage candidates including AK1960 and ALM0106 to pharmaceutical partners such as Asahi Kasei Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTsukuba, Japan
HQ citystring
Tsukuba
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
small molecule drugs, drug discovery platform, preclinical compounds, pharmaceutical licensing, autoimmune therapeutics
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Drug Discovery
Social media profiles1 record
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Alchemedicine is a drug discovery company that uses its proprietary HiSAP® synthesis platform to identify and develop novel small molecule therapeutics that improve upon the limitations of existing drugs, including weak efficacy, strong side effects, and insufficient pharmacokinetics. The company advances a pipeline of preclinical and clinical-stage candidates and monetizes them through exclusive global licensing agreements with pharmaceutical partners such as Asahi Kasei Pharma.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Alchemedicine is a drug discovery research company specializing in novel small molecule pharmaceuticals. The company's core offering is the proprietary HiSAP® drug discovery platform, which applies proprietary synthesis technology to improve upon existing drug candidates by addressing limitations such as weak efficacy, strong side effects, and insufficient in vivo pharmacokinetics. The company operates a pipeline of therapeutic candidates at various stages: AK1960 (selective ETA receptor antagonist) has advanced to Phase I clinical trials for refractory diseases including chronic kidney disease; ALM0106 is in exclusive evaluation for autoimmune diseases; and multiple preclinical lead compounds targeting autoimmune diseases have been exclusively licensed to Asahi Kasei Pharma. The company also holds patents for oligopeptide derivatives (MMP-2/MMP-9 inhibitors) developed through Accure Therapeutics.

Product and service1 record
1HiSAP® Drug Discovery Platform
Partnership4 partners
1Sekisui Medical Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Non-clinical research collaboration with Sekisui Medical Co., Ltd. Third-party allocation of new shares implemented and underwritten.

alchemedicine.com
2Asahi Kasei Pharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Exclusive global license agreement granting worldwide rights to research, develop, manufacture, and commercialize novel preclinical lead compounds discovered using Alchemedicine's HiSAP platform for autoimmune diseases. Second licensing agreement between the two companies, following initial partnership in June 2022. Supports Asahi Kasei Group's goal of achieving $3 billion in pharmaceutical sales by 2030.

businesswire.com
3Asahi Kasei Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on novel Endothelin A receptor antagonist AK1960, a small molecule derived from Alchemedicine's HiSAP platform. Phase I clinical study initiated for treatment of refractory diseases including chronic kidney disease. Companies leverage Calliditas Therapeutics AB and Veloxis Pharmaceuticals to advance the program toward global markets.

businesswire.com
4Sekisui Medical Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for non-clinical research operations with Sekisui Medical Co., Ltd. Includes third-party allocation of new shares (third-party allocation increase of capital).

alchemedicine.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Eisai Co., Ltd.
TypeBroad incumbent
Description

Major Japanese pharma with extensive external sourcing of early-stage discovery assets. Comparable as a potential acquirer/licensor of platform-generated small-molecule candidates similar to those produced by Alchemedicine.

TypeDirect peer
Description

Japanese drug discovery company developing antibody and small-molecule therapeutics through proprietary platforms and out-licensing to pharma. Directly comparable in business model (platform-based discovery + pharma licensing) and Japan-headquartered.

TypeBroad incumbent
Description

Largest Japanese pharma with global reach and active licensing/partnering of discovery-stage assets. Comparable as a potential anchor partner for a Japanese small-molecule discovery platform.

4PeptiDream
TypeDirect peer
Description

Japanese peptide/small-molecule discovery platform company that licenses novel therapeutic candidates to global pharma partners. Highly comparable to Alchemedicine as a Japan-based discovery platform monetized via licensing deals.

5Carna Biosciences
TypeDirect peer
Description

Japanese kinase-focused drug discovery and development company. Comparable in size, geography, and discovery-platform approach, with partnered clinical assets.

TypeBroad incumbent
Description

Large Japanese pharmaceutical company that in-licenses discovery-stage programs. Relevant as a potential future licensing partner given similar deal structures used in Alchemedicine's existing Asahi Kasei Pharma agreements.

TypeBroad incumbent
Description

Japanese clinical-stage biotech that has leveraged partnerships and licensing structures to advance pipeline assets. Comparable in Japan-listed/biotech-partnering orientation though operating in a different modality (cell therapy).

8RaQualia Pharma
TypeDirect peer
Description

Japan-based small-molecule drug discovery company focused on ion channel and GPCR targets, generating candidates for partnership with global pharma. Comparable as a Japanese small-molecule discovery firm commercializing via licensing.

9Asahi Kasei Pharma
TypeOthers
Description

Major Japanese pharmaceutical company and Alchemedicine's central licensing partner. Included as an ecosystem participant — understanding Asahi Kasei Pharma's strategy and budget is essential to valuing Alchemedicine's pipeline.

10Sosei Group (Sosei Heptares)
TypeBroad incumbent
Description

Japan-headquartered global drug discovery company with a GPCR-focused platform, partnered broadly with major pharma. Larger and more advanced, but directly comparable as a Japan-based platform-discovery licensing business.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alchemedicine

Drug Discoveryalchemedicine.com

Alchemedicine is a Tsukuba, Japan-based biotechnology company that uses its proprietary HiSAP® drug discovery platform to develop improved small-molecule therapeutics, licensing preclinical and clinical-stage candidates including AK1960 and ALM0106 to pharmaceutical partners such as Asahi Kasei Pharma.

What Alchemedicine does

Alchemedicine (株式会社アークメディスン) is a privately held Japanese biotechnology company headquartered in Tsukuba, founded in 2019 and operating with 1-10 employees. The company specializes in the research and development of new low-molecular-weight pharmaceuticals, anchored by its proprietary HiSAP® drug discovery synthesis platform. HiSAP® is described as a synthesis technology designed to rapidly address limitations of existing drug candidates, including weak efficacy, strong side effects, and inadequate in vivo pharmacokinetics, and is positioned as applicable across multiple disease areas with high unmet medical need.

Alchemedicine firmographics

Firmographics
Name
Alchemedicine
Legal name
株式会社アークメディスン
Website
https://alchemedicine.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Alchemedicine is a Tsukuba, Japan-based biotechnology company that uses its proprietary HiSAP® drug discovery platform to develop improved small-molecule therapeutics, licensing preclinical and clinical-stage candidates including AK1960 and ALM0106 to pharmaceutical partners such as Asahi Kasei Pharma.
Ownership category
akta.pro rank

Alchemedicine industry classification

Industry
Product category
Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Small molecule drugs
  • Drug discovery platform
  • Preclinical compounds
  • Pharmaceutical licensing
  • Autoimmune therapeutics

Where Alchemedicine is headquartered

Location

Headquarters

HQ city
Tsukuba
HQ country
Japan
HQ region
Asia

Markets served

Alchemedicine business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Alchemedicine product offering

Product offering

Core offering

Alchemedicine is a drug discovery company that uses its proprietary HiSAP® synthesis platform to identify and develop novel small molecule therapeutics that improve upon the limitations of existing drugs, including weak efficacy, strong side effects, and insufficient pharmacokinetics. The company advances a pipeline of preclinical and clinical-stage candidates and monetizes them through exclusive global licensing agreements with pharmaceutical partners such as Asahi Kasei Pharma.

Product overview

Alchemedicine is a drug discovery research company specializing in novel small molecule pharmaceuticals. The company's core offering is the proprietary HiSAP® drug discovery platform, which applies proprietary synthesis technology to improve upon existing drug candidates by addressing limitations such as weak efficacy, strong side effects, and insufficient in vivo pharmacokinetics. The company operates a pipeline of therapeutic candidates at various stages: AK1960 (selective ETA receptor antagonist) has advanced to Phase I clinical trials for refractory diseases including chronic kidney disease; ALM0106 is in exclusive evaluation for autoimmune diseases; and multiple preclinical lead compounds targeting autoimmune diseases have been exclusively licensed to Asahi Kasei Pharma. The company also holds patents for oligopeptide derivatives (MMP-2/MMP-9 inhibitors) developed through Accure Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • HiSAP® Drug Discovery Platform

Companies that use Alchemedicine

Customer profile

Segments1 record

Ideal customer profiles2 records

Alchemedicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Alchemedicine partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Sekisui Medical Co., Ltd.coreStrategic or Co-development Partner · 1 June 2026Non-clinical research collaboration with Sekisui Medical Co., Ltd. Third-party allocation of new shares implemented and underwritten.
  • Asahi Kasei PharmacoreStrategic or Co-development Partner · 3 February 2026Exclusive global license agreement granting worldwide rights to research, develop, manufacture, and commercialize novel preclinical lead compounds discovered using Alchemedicine's HiSAP platform for autoimmune diseases. Second licensing agreement between the two companies, following initial partnership in June 2022. Supports Asahi Kasei Group's goal of achieving $3 billion in pharmaceutical sales by 2030.
  • Asahi Kasei PharmacoreStrategic or Co-development PartnerCollaboration on novel Endothelin A receptor antagonist AK1960, a small molecule derived from Alchemedicine's HiSAP platform. Phase I clinical study initiated for treatment of refractory diseases including chronic kidney disease. Companies leverage Calliditas Therapeutics AB and Veloxis Pharmaceuticals to advance the program toward global markets.
  • Sekisui Medical Co., Ltd.coreStrategic or Co-development PartnerCollaboration for non-clinical research operations with Sekisui Medical Co., Ltd. Includes third-party allocation of new shares (third-party allocation increase of capital).

Recent moves6 records

Expansion highlights5 records

Alchemedicine competitors and assessment

Company assessment

Broad incumbents

  • Eisai Co., Ltd. Major Japanese pharma with extensive external sourcing of early-stage discovery assets. Comparable as a potential acquirer/licensor of platform-generated small-molecule candidates similar to those produced by Alchemedicine.
  • Takeda Pharmaceutical: Largest Japanese pharma with global reach and active licensing/partnering of discovery-stage assets. Comparable as a potential anchor partner for a Japanese small-molecule discovery platform.
  • Otsuka Pharmaceutical: Large Japanese pharmaceutical company that in-licenses discovery-stage programs. Relevant as a potential future licensing partner given similar deal structures used in Alchemedicine's existing Asahi Kasei Pharma agreements.
  • Healios KK: Japanese clinical-stage biotech that has leveraged partnerships and licensing structures to advance pipeline assets. Comparable in Japan-listed/biotech-partnering orientation though operating in a different modality (cell therapy).
  • Sosei Group (Sosei Heptares): Japan-headquartered global drug discovery company with a GPCR-focused platform, partnered broadly with major pharma. Larger and more advanced, but directly comparable as a Japan-based platform-discovery licensing business.

Direct peers

  • Chiome Bioscience: Japanese drug discovery company developing antibody and small-molecule therapeutics through proprietary platforms and out-licensing to pharma. Directly comparable in business model (platform-based discovery + pharma licensing) and Japan-headquartered.
  • PeptiDream: Japanese peptide/small-molecule discovery platform company that licenses novel therapeutic candidates to global pharma partners. Highly comparable to Alchemedicine as a Japan-based discovery platform monetized via licensing deals.
  • Carna Biosciences: Japanese kinase-focused drug discovery and development company. Comparable in size, geography, and discovery-platform approach, with partnered clinical assets.
  • RaQualia Pharma: Japan-based small-molecule drug discovery company focused on ion channel and GPCR targets, generating candidates for partnership with global pharma. Comparable as a Japanese small-molecule discovery firm commercializing via licensing.

Others

  • Asahi Kasei Pharma: Major Japanese pharmaceutical company and Alchemedicine's central licensing partner. Included as an ecosystem participant — understanding Asahi Kasei Pharma's strategy and budget is essential to valuing Alchemedicine's pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Alchemedicine social profiles

Digital presence

Alchemedicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alchemedicine leadership team

Management profile

Number of profiles

Profiles1 record

Alchemedicine funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alchemedicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alchemedicine

What does Alchemedicine do?

Alchemedicine is a drug discovery company that uses its proprietary HiSAP® synthesis platform to identify and develop novel small molecule therapeutics that improve upon the limitations of existing drugs, including weak efficacy, strong side effects, and insufficient pharmacokinetics. The company advances a pipeline of preclinical and clinical-stage candidates and monetizes them through exclusive global licensing agreements with pharmaceutical partners such as Asahi Kasei Pharma.

Is Alchemedicine a public or private company?

Alchemedicine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alchemedicine founded?

Alchemedicine was founded in 2022. It employs 1 to 10 people.

Where is Alchemedicine based?

Alchemedicine is headquartered in Tsukuba, Japan, in the Asia region.

Who are Alchemedicine's main competitors?

Broad incumbents on record are Eisai Co., Ltd., Takeda Pharmaceutical, Otsuka Pharmaceutical, Healios KK and Sosei Group (Sosei Heptares). Direct peers are Chiome Bioscience, PeptiDream, Carna Biosciences and RaQualia Pharma. Asahi Kasei Pharma is listed as an others.

Does Alchemedicine have an API?

No public API is recorded for Alchemedicine.

What industry is Alchemedicine in?

Alchemedicine's product category is Drug Discovery. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAsahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead CompoundsAsahi Kasei Pharma executed an exclusive global license agreement with Alchemedicine on February 3, 2026, gaining worldwide rights to research, develop, manufacture, and commercialize novel preclinical lead compounds discovered using Alchemedicine's HiSAP™ drug discovery platform, with potential therapeutic applications across multiple autoimmune diseases. This represents the second licensing agreement between the two companies, following an initial partnership in June 2022, signaling a deepened strategic collaboration built on proven success. The agreement supports Asahi Kasei Group's stated goal of achieving $3 billion in pharmaceutical sales by 2030 and positions the pharmaceuticals business, designated as a First Priority area in its medium-term management plan, for continued global expansion through open innovation.PharmiWeb.comAsahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead CompoundsAsahi Kasei Pharma executed an exclusive global license agreement with Alchemedicine on February 3, 2026, obtaining worldwide rights to research, develop, manufacture, and commercialize novel preclinical lead compounds identified using Alchemedicine's HiSAP™ drug discovery platform, with potential therapeutic applications for multiple autoimmune diseases. This marks the second license agreement between the two companies, building on an initial partnership established in June 2022 and reflecting a deepened strategic collaboration. The agreement supports Asahi Kasei's goal of achieving $3 billion in pharmaceutical sales by 2030 as part of its First Priority business strategy.Stock TitanAsahi Kasei starts Phase I trial of AK1960 drugAsahi Kasei Pharma and Alchemedicine have announced that their drug candidate AK1960 has advanced to a Phase I clinical trial for refractory diseases, marking a strategic milestone for the companies. The drug, a novel ETA receptor antagonist, has shown efficacy in animal models and will be developed for global markets. The companies plan to leverage additional partners to further develop AK1960 while emphasizing their commitment to innovative healthcare solutions.Business Wire BlogAsahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory DiseasesAsahi Kasei Pharma and Alchemedicine have advanced their novel Endothelin A receptor antagonist AK1960 into a Phase I clinical study, following successful preclinical results for the treatment of refractory diseases. AK1960, a small molecule drug derived from Alchemedicine's HiSAP™ platform, demonstrated efficacy in animal models for kidney diseases and is intended for the treatment of refractory chronic kidney disease and other conditions resistant to standard therapies. The companies, which entered an exclusive license agreement in 2022 with Asahi Kasei acquiring worldwide development and commercialization rights, will leverage Calliditas Therapeutics and Veloxis Pharmaceuticals to advance the program toward global markets.PharmiWeb.comAsahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory DiseasesAsahi Kasei Pharma and Alchemedicine have advanced their novel Endothelin A receptor antagonist AK1960 into a Phase I clinical study following successful preclinical results, with studies being conducted in Japan for the treatment of refractory diseases including chronic kidney disease. AK1960, a small molecule with high selectivity derived from Alchemedicine's HiSAP™ platform, was licensed to Asahi Kasei Pharma in 2022 with worldwide development and commercialization rights. The companies will leverage Calliditas Therapeutics AB and Veloxis Pharmaceuticals to advance the program, which is intended for the global market despite current trials being limited to Japan.PharmiWeb.comAsahi Kasei Pharma and Alchemedicine advance a novel therapeutic candidate into Phase I study for the treatment of refractory diseasesAsahi Kasei Pharma and Alchemedicine announced that their novel ETA receptor antagonist AK1960 has advanced into a Phase I clinical study following successful preclinical results, representing a significant milestone in their collaboration. The drug, developed from Alchemedicine's HiSAP™ platform and targeting refractory diseases including chronic kidney disease, will have preclinical and Phase I studies conducted in Japan while targeting the global market. The Asahi Kasei Group plans to leverage Calliditas Therapeutics and Veloxis Pharmaceuticals to support the continued development of AK1960 as part of its strategy to grow its Pharmaceuticals business.BioSpaceAsahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory DiseasesAsahi Kasei Pharma, in collaboration with Alchemedicine, has advanced AK1960, a novel Endothelin A receptor antagonist, into a Phase I clinical study following successful preclinical results. AK1960 is a small molecule derived from Alchemedicine's HiSAP platform, intended to treat refractory diseases including chronic kidney disease, with the companies having entered an exclusive license agreement in 2022 granting Asahi Kasei worldwide development and commercialization rights. While preclinical and Phase I studies are conducted in Japan, the program targets the global market, with Asahi Kasei leveraging Calliditas Therapeutics and Veloxis Pharmaceuticals for further development.